Blacksmith Medicines and Forge Therapeutics have signed a definitive merger agreement to leverage their combined chemistry platforms, creating a biopharma dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes, with initial focus on oncology and infection.
“We are excited to unveil the merger of Blacksmith and Forge, which we believe will be transformational for both companies. Prospects are very bright for the new Blacksmith, as we are now able to expand our metalloenzyme platform, advance our internal and partnered programs, and create increased value for our shareholders by discovering first-in-class and best-in-class medicines,” said Zachary Zimmerman, Ph.D., CEO and co-founder of Blacksmith.
“Our target strategy is to focus on metalloenzymes of significant unmet need and high pharma interest, targets with validated biology that have been challenging to drug due to chemistry limitations that we can solve with our platform.”
The Blacksmith platform has been validated through multiple pharmaceutical partnerships, including deals with Roche, Eli Lilly, and Basilea, which have the potential to earn over $800m in milestone payments plus royalties.
Furthermore, the company currently has earned non-dilutive federal awards of up to $25.3m to fully fund its infectious disease programs to the end of Phase 1. Blacksmith also has emerging precision oncology programs focused on novel synthetic lethality targets involved in the DNA Damage Response.
Blacksmith investors include Evotec A.G., MagnaSci Ventures, MP Healthcare Partners, Alexandria Venture Investments, and Eli Lilly.
